We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Cizzle Biotechnology Holdings Plc | CIZ | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.80 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.80 | 1.80 | 1.80 | 1.80 | 1.80 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 25/7/2024 06:05 by dplewis1 hTTps://www.londonst |
Posted at 18/7/2024 06:05 by dplewis1 Commercialisation.. hTTps://www.londonst |
Posted at 14/4/2024 14:10 by secretsqu Whilst I can't speak for LLAI, I'm rather intrigued by your comment that all 3 Company's cash burn was substantial.My intrigue stems from your comparison of ONC v Ciz, given that Ciz's annual cash burn is circa 20% that of ONC. |
Posted at 13/4/2024 20:00 by cirlbunting1 Apologies, I didn't add context to my statement. In short - I deep dived ONC about 1 (maybe) 2 years ago. When doing so, I had looked closely into CIZ and LLAI too. Out of the 3 companies and in terms of early detection - ONC's biomarkers looked to be a few years ahead (granted tech was different) and most promising (in terms of results). Even so, ONC didn't really fill me with much confidence especially given the larger players out there with deeper pockets and better results. I noticed cash burn on all 3 companies was quite substantial and in addition, all 3 would require a few placements nevertheless to keep afloat. I also came to the conclusion that CIZ was the most vulnerable. Anyways.. that's my 2 pens worth. |
Posted at 01/4/2024 08:54 by geoff98 Why has someone loosely related to the company (detail of 'partnership' largely unknown) set up a company in the US & called it Cizzle Bio?This information is publicly available & is, therefore, an announcement. Will this announcement have a material impact on the share price? Almost certainly, yes, in my view. One way or another. Why has CIZ made no announcement via RNS to the shareholders regarding this? |
Posted at 08/12/2023 21:40 by oapknob1 Owed them ? Previously posted So CIZ paid out £255,000 cash for economic interest in AZD1656. Then get paid £200,000 by SGSC so £55,000 paid out and the 5% interest was settled with issuing shares in CIZ to a value of £1,880,000. They executed the put and received £3,250,000 worth NASDAQ shares in CDT at $10 a share. Whats terrible ? (Other than current CDT share price)20 September 2021"SGSC to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street's therapeutic asset AZD1656 of up to GBP5 million, plus potentially further payments from the use of a companion diagnostic.""Under the full commercial contract entered into, in consideration of the potential future royalty stream from the commercialisation of AZD1656 , Cizzle Biotechnology is to pay GBP135,000 to SGSC."22 October 2021"Research and Development agreement worth up to GBP1 million signed for potential autoimmune disease testing and possible additional companion diagnostics.""SGSC will pay Cizzle Biotechnology GBP200,000 upfront on commencement of the project and then further milestone payments totalling up to GBP1 million. "14 February 2022Agreement with Conduit and SGSC to acquire a 5% economic interest for a total consideration of GBP1.88 million, to be settled in new Cizzle ordinary shares at a price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February 2022"The Agreement is in addition to the Company's existing interest in AZD 1656 as announced on 20 September 2021"29 September 2022has settled the remaining consideration of GBP880,000 due under the Agreement through the issue of 22,000,000 new ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at 4.0p per share (the "Agreement Shares") to Conduit.19 December 2022"Put Option for Sale of Economic Interest and Royalty Sharing Agreement in AZD1656""Cizzle has agreed to pay Conduit GBP120,000 in cash as the premium for the Option" |
Posted at 02/12/2023 17:04 by oapknob1 So CIZ paid out £255,000 cash for economic interest in AZD1656. Then get paid £200,000 by SGSC so £55,000 paid out and the 5% interest was settled with issuing shares in CIZ to a value of £1,880,000. They executed the put and received £3,250,000 worth NASDAQ shares in CDT at $10 a share. Whats terrible ? (Other than current CDT share price)20 September 2021"SGSC to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street's therapeutic asset AZD1656 of up to GBP5 million, plus potentially further payments from the use of a companion diagnostic.""Under the full commercial contract entered into, in consideration of the potential future royalty stream from the commercialisation of AZD1656 , Cizzle Biotechnology is to pay GBP135,000 to SGSC."22 October 2021"Research and Development agreement worth up to GBP1 million signed for potential autoimmune disease testing and possible additional companion diagnostics.""SGSC will pay Cizzle Biotechnology GBP200,000 upfront on commencement of the project and then further milestone payments totalling up to GBP1 million. "14 February 2022Agreement with Conduit and SGSC to acquire a 5% economic interest for a total consideration of GBP1.88 million, to be settled in new Cizzle ordinary shares at a price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February 2022"The Agreement is in addition to the Company's existing interest in AZD 1656 as announced on 20 September 2021"29 September 2022has settled the remaining consideration of GBP880,000 due under the Agreement through the issue of 22,000,000 new ordinary shares of 0.01 pence each ("Ordinary Shares") in the Company at 4.0p per share (the "Agreement Shares") to Conduit.19 December 2022"Put Option for Sale of Economic Interest and Royalty Sharing Agreement in AZD1656""Cizzle has agreed to pay Conduit GBP120,000 in cash as the premium for the Option" |
Posted at 25/9/2023 09:52 by smithie6 ...well......if CIZ exercises it's option & bags £X million then CIZ has a cash pile ...which is a big % of its cap. value - reduces risk for shareholders - deletes any risk of a capital raise by issuing new shares (which often reduces the share price unless there is good news at the same time) - the takeover value of CIZ goes up - gives CIZ more power & respect in any negotiations that it does including with partners & places that CIZ pays to do work (since they all know that CIZ has a wadge of cash so it will be around for at least X years & can pay its bills) & it gives the mkt confidence or a smile about the capabilities of the bod to do profitable deals. This option deal has been very profitable for CIZ, assuming they cash in. |
Posted at 16/3/2023 15:46 by smithie6 RNS"09/09/2021 7:00am UK Regulatory (RNS & others) TIDMCIZ RNS Number : 1857L 9 September 2021 Cizzle Biotechnology Holdings Plc Encouraging progress on collaboration with St George Street Capital St George Street Capital announces results of the Phase II ARCADIA study of AZD1656 in diabetic patients with COVID-19 Cizzle Biotechnology, the UK based diagnostics developer, is pleased to provide an update on its collaboration with St George Street Capital ("SGSC"), the UK-based biomedical charity. As announced on 22 June 2021, Cizzle Biotechnology signed a Memorandum of Understanding ("MoU") with SGSC covering a proposed collaboration between the parties to develop a companion diagnostic platform for which Cizzle Biotechnology will receive fees of up to GBP1 million. Further, under the MoU, SGSC has agreed to grant Cizzle Biotechnology potential future royalty payments from the commercialisation of St George Street Capital's therapeutic asset AZD1656 of up to GBP5 million, plus potentially further payments from the use of the companion diagnostic. SGSC has today announced the results of the ARCADIA trial; a phase II, randomised, double-blind, placebo-controlled clinical trial in 153 patients to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The initiation of the ARCADIA trial was the result of an existing collaboration between SGSC and AstraZeneca as part of its Open Innovation Programme and it was funded by international investment through Excalibur Medicines Ltd and an HM Government grant through the UKRI/Innovate UK programme. SGSC reported there are no safety concerns raised regarding the use of AZD1656 in this patient population and they confirmed that there were strong trends in favour of AZD1656 with respect to mortality. The data from the ARCADIA trial supports continued investigation of AZD1656 for the treatment of diabetics with COVID-19 and in light of these encouraging results, St George Street Capital will undertake commercial discussions with potential licencees and/or fundraise for further clinical trials to investigate AZD1656 in a larger study. Following signature of the MoU, Cizzle Biotechnology expects to enter into a full commercial contract in due course. Whilst any royalty payments to Cizzle Biotechnology are contingent on the successful development of AZD1656, today's announcement by SGSC on the positive results from its clinical trial is significant step forward in Cizzle Biotechnology realising the full potential of its royalty rights in AZD1656. Commenting, Allan Syms, Executive Chairman of Cizzle Biotechnology, said: "We congratulate St George Street Capital on the success of its ARCADIA clinical trial. This further supports our longer-term ambitions to work closely with St George Street Capital and to leverage the technology and know-how of Cizzle Biotechnology to match diagnostic capabilities with therapeutic need. This will increase product opportunities and potential revenue streams for the Company, in addition to our core focus on developing our blood test for the early detection of a majority of the different forms of lung cancer." Commenting, Professor John Martin of UCL, Chairman of SGSC, said: "The completion of ARCADIA marks a significant milestone in the history of the charity St George Street Capital. We have demonstrated our ability to rapidly deliver a clinical trial in an area of unmet clinical need, thus fulfilling our mission to accelerate the development of new treatments for people who need them. The promising results from this trial indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for COVID-19 - independent of viral mutations - initiating a new wave of therapies for clinicians in meeting this global challenge." Enquiries: Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) ......." |
Posted at 16/3/2023 15:22 by smithie6 there is a 3rd RNS about CIZ & deals with Conduit/SGSA14th Feb. 2022 Cizzle Biotechnology Holdings PLC 14 February 2022 This announcement contains inside information for the purposes of article 7 of EU Regulation 596/2014 which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018 ("UK MAR") . Upon the publication of this announcement this inside information is now considered to be within the public domain. 14 February 2022 Cizzle Biotechnology Holdings Plc ("Cizzle Biotechnology", "Cizzle" or the "Company") Acquisition of Royalty Deal in Inflammatory Pulmonary and Cardiovascular Diseases Cizzle Biotechnology, the UK based diagnostics developer, is pleased to announce that it has entered into a definitive agreement (the "Agreement") with Conduit Pharmaceuticals Limited ("Conduit") and St George Street Capital Limited ("SGSC") to acquire a 5% economic interest in the commercialisation of the AZD 1656 asset or other such assets being developed by Conduit or SGSC to treat inflammatory pulmonary and cardiovascular disease (the "Economic Interest"). Highlights -- Agreement with Conduit and SGSC to acquire a 5% economic interest for a total consideration of GBP1.88 million, to be settled in new Cizzle ordinary shares at a price of 4.0p per share, a 56.9% premium to the closing mid-market price on 11 February 2022 -- The Agreement is in addition to the Company's existing interest in AZD 1656 as announced on 20 September 2021 -- SGSC recently reported the successful completion of the AZD 1656 ARCADIA clinical trial in Covid-19 and SGSC and Conduit are in discussions with multiple pharmaceutical companies about licensing opportunities for AZD 1656 for Covid-19 and potentially for further indications -- The Agreement supports the Company's ambitions to expand its target customer base into the pharmaceutical industry and is in line with its strategy of building a portfolio of early cancer detection tests, companion diagnostics and royalty bearing stakes in significant drug assets Allan Syms, Executive Chairman of Cizzle Biotechnology, said "The agreement announced today represents an important extension to our close relationship with SGSC and Conduit. On 20 September 2021 we announced we had acquired a stake in SGSC's AZD 1656 asset, providing the opportunity for the Company to receive royalty payments of up to GBP5 million and shortly after SGSC contracted the Company to develop an associated companion diagnostic test for which we will receive fees of up to GBP1 million. "We are now pleased to have the opportunity to increase our stake by an additional 5% in AZD 1656, but significantly the Economic Interest will be uncapped. This new Agreement supports the Company's ambitions to expand its target customer base in the pharmaceutical industry and through a strategy of building a portfolio of early cancer detection tests, companion diagnostics and royalty bearing stakes in significant drug assets significantly increase shareholder value." Background SGSC is a UK-based medical-charity led by a group of highly decorated academics and ex-pharma executives formed to deliver much needed treatments to patients. SGSC's strategy is to take clinical-ready assets from pharmaceutical companies and to progress them through Phase II medical trials, before licensing them on for Phase III trials and commercialisation in order to create a return for investors and the charity alike. SGSC recently reported the successful completion of the AZD 1656 ARCADIA clinical trial in Covid-19 and SGSC and Conduit are in discussion with multiple pharmaceutical companies about licensing opportunities for AZD 1656 in both Covid-19 and potentially in further indications. Conduit is the exclusive funding partner to the Charity. The ARCADIA trial data, that treated inflammatory pulmonary and cardiovascular disease caused by Covid-19, showed a strong trend towards reduced mortality in patients receiving AZD 1656. The strong trend to improved mortality for patients on AZD 1656 was observed on top of patients receiving other medication as part of standard of care. AZD 1656 was also shown to be well-tolerated in this patient population with no serious adverse reactions (SARs) occurring. Overall, no safety concerns were identified regarding the use of AZD 1656 in this patient population. Furthermore, SGSC has shown there was a significant increase in the migration of the Regulatory T Cells ("Tregs") from the patients who had taken the drug compared to the Tregs from the patients who had not. Tregs are a specialised subpopulation of T cells that act to suppress immune response and combat damaging cells, potentially reducing serious cardiovascular and lung diseases which are causative in the development of lung cancer, which Cizzle is developing its diagnostic test to identify. Under the Agreement Cizzle Biotechnology will receive 5% of all such sums received by SGS pursuant to any AstraZeneca ("AZ") commercialisation or sub-license commercialisation of the AZ asset in inflammatory pulmonary and cardiovascular diseases, after the deduction of certain sums. Consideration for the Agreement Under the terms of the Agreement, Cizzle will pay consideration of GBP1.88 million to SGS for the Economic Interest. Of the consideration payable, GBP1.0 million (the "Initial Consideration") will be satisfied by the issue of 25,000,000 new ordinary shares in the Company (the "Consideration Shares"), at a price of 4.0 pence per Consideration Share, being a premium of 56.9 per cent. to the Company's closing mid-market price of 2.55 pence on 11 February 2022. The remaining consideration of GBP880,000 will be payable in new ordinary shares in the Company issued at 4.0 pence per share, on the sooner of receiving shareholder approval to issue the shares or the first anniversary of completion. Total Voting Rights On completion of payment of the Initial Consideration, Conduit will hold 25,000,000 ordinary shares in Cizzle representing 8.98 per cent. of the issued share capital of the Company, as enlarged by the issue of the Consideration Shares. The Company has applied for admission of the 25,000,000 Initial Consideration new Ordinary Shares to trading on the Standard Segment of the Official List and the Main Market of the London Stock Exchange ("Admission"). It is expected that Admission will become effective on or around 17 February 2022. The Company's issued ordinary share capital on Admission will consist of 278,447,788 ordinary shares of 0.1 pence each, all with voting rights. The Company holds no ordinary shares in Treasury. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules. Enquiries: Cizzle Biotechnology Holdings Via IFC Advisory plc Allan Syms (Executive Chairman) Allenby Capital Limited +44(0) 20 33285656 John Depasquale Alex Brearley Novum Securities Limited +44(0) 20 7399 9400 Colin Rowbury Jon Bellis IFC Advisory Limited +44(0) 20 3934 6630 Tim Metcalfe cizzle@investor-focu Florence Chandler Notes to Editors: About Cizzle Biotechnology...... END |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
